Tipranavir: Difference between revisions
imported>David E. Volk m (minor) |
imported>David E. Volk (Chem infobox) |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
[[Image:Tipranavir structure.jpg|right|thumb|250px|{{#ifexist:Template:Tipranavir structure.jpg/credit|{{Tipranavir structure.jpg/credit}}<br/>|}}Tipranavir]] | |||
{{Chem infobox | |||
|align=right | |||
|image=[[Image:Tipranavir structure.jpg|right|thumb|250px|{{#ifexist:Template:Tipranavir structure.jpg/credit|{{Tipranavir structure.jpg/credit}}<br/>|}}Tipranavir]] | |||
|width=250px | |||
|molname=tipranavir | |||
|synonyms= Aptivus® | |||
|molformula= C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S | |||
|molmass= 602.6643 | |||
|uses=HIV | |||
|properties=protease inhibitor | |||
|hazards=see drug interactions | |||
|iupac= see chemistry section | |||
|casnumber= 174484-41-4 | |||
}} | |||
'''Tipranavir''' ('''TPV'''), sold under the brand name '''Aptivus®''', is a nonpeptidic [[protease inhibitor]] drug used to treat [[HIV]]/[[AIDS]] in combination with [[ritonavir]]. It is used for patients with extensive previous treatment of those infected with HIV strains that have multiple protease inhibitor resistance. Tipranavir blocks the function of protease enzymes sothat the Gag and Gag-Pol polyprotein cannot be cleaved into individual active proteins, thus blocking the formation of infectious mature viral particles. Such inhibitors all almost always used in a combination therapy with other anti-HIV drugs. | '''Tipranavir''' ('''TPV'''), sold under the brand name '''Aptivus®''', is a nonpeptidic [[protease inhibitor]] drug used to treat [[HIV]]/[[AIDS]] in combination with [[ritonavir]]. It is used for patients with extensive previous treatment of those infected with HIV strains that have multiple protease inhibitor resistance. Tipranavir blocks the function of protease enzymes sothat the Gag and Gag-Pol polyprotein cannot be cleaved into individual active proteins, thus blocking the formation of infectious mature viral particles. Such inhibitors all almost always used in a combination therapy with other anti-HIV drugs. | ||
== Chemistry == | |||
Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S. | Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C<sub>31</sub>H<sub>33</sub>F<sub>3</sub>N<sub>2</sub>O<sub>5</sub>S. | ||
Revision as of 08:48, 22 March 2008
|
| |||||||
| tipranavir | |||||||
| |||||||
| Uses: | HIV | ||||||
| Properties: | protease inhibitor | ||||||
| Hazards: | see drug interactions | ||||||
| |||||||
Tipranavir (TPV), sold under the brand name Aptivus®, is a nonpeptidic protease inhibitor drug used to treat HIV/AIDS in combination with ritonavir. It is used for patients with extensive previous treatment of those infected with HIV strains that have multiple protease inhibitor resistance. Tipranavir blocks the function of protease enzymes sothat the Gag and Gag-Pol polyprotein cannot be cleaved into individual active proteins, thus blocking the formation of infectious mature viral particles. Such inhibitors all almost always used in a combination therapy with other anti-HIV drugs.
Chemistry
Its IUPAC chemical name is Name N-[3-[(1R)-1-[(6R)-2-hydroxy-4-oxo-6-(2-phenylethyl)-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide and its chemical formula is C31H33F3N2O5S.
External Links
- Tipranavir - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Template:MedMaster
- Template:DrugBank